<DOC>
	<DOCNO>NCT00211185</DOCNO>
	<brief_summary>Study ONTAK CHOP ( chemotherapy drug ) find ability make Peripheral T-cell lymphoma disappear ( period time ) potentially lengthen life . The study also compare kind side effect drug cause often occur . The hypothesis patient newly diagnose peripheral T-Cell lymphoma , give ONTAK + CHOP , tolerate treatment 20 % improvement response rate compare CHOP alone .</brief_summary>
	<brief_title>A Study ONTAK CHOP Newly Diagnosed , Peripheral T-Cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Denileukin diftitox</mesh_term>
	<criteria>Pathological diagnosis peripheral Tcell lymphoma one follow histology per REAL classification : peripheral Tcell lymphoma ( unspecified ) , anaplastic large cell lymphoma CD30+ , angioimmunoblastic Tcell lymphoma , nasal/nasal type T/NK cell lymphoma , intestinal Tcell lymphoma , hepatosplenic Tcell lymphoma , subcutaneous panniculitic Tcell lymphoma . Treatment na√Øve except prior radiation single cycle CHOP . Patients must least one clearcut bidimensionally measurable site physical exam and/or compute tomography . Prior radiation therapy localize disease allow long irradiated area mediastinal area site measurable disease . Therapy must complete least 4 week enrollment study . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 . At least 18 year age . Adequate bone marrow reserve , indicate absolute neutrophil count ( ANC ) &gt; equal 1000/microL , platelet &gt; equal 50,000/microL ( 25,000/MicroL thrombocytopenia secondary bone marrow involvement lymphoma ) , hemoglobin &gt; equal 8 g/dL . Adequate liver function , indicate bilirubin &lt; equal 1.5 time upper limit normal ( ULN ) , alanine transaminase ( ALT ) &lt; equal 2 time ULN aspartate transaminase ( AST ) &lt; equal 2.0 time ULN , albumin &gt; equal 3.0 g/dL . Adequate renal function , indicate serum creatinine &lt; equal 2.5 mg/dL . Women childbearing potential sexually active male agree use accept effective method contraception . Able give inform consent . Diagnosis Mycosis Fungoides Sezary Syndrome . Active Hepatitis B Hepatitis C infection . Known HIV infection ( HIV test require ) . Patients active infection require specific antiinfective therapy eligible sign infection resolve continue treatment appropriate give outpatient basis . Previous doxorubicin therapy cumulative dose &gt; 100 mg/m2 . Left Ventricular Ejection Fraction ( LVEF ) &lt; 50 % . Patients pregnant breastfeeding . Prior invasive malignancy within past 5 year . Allergy history allergy diphtheria toxin IL2 . Preexisting severe cardiovascular disease ( e.g . CHF , Severe CAD , cardiomyopathy , MI within past 3 month , arrhythmia ) require ongoing treatment . Ongoing antineoplastic chemotherapy , radiation , hormonal ( exclude contraceptive ) immunotherapy , investigational medication within past 30 day . Patients deep vein thrombosis within 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>